Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O14862

UPID:
AIM2_HUMAN

ALTERNATIVE NAMES:
Absent in melanoma 2

ALTERNATIVE UPACC:
O14862; A8K7M7; Q5T3V9; Q96FG9

BACKGROUND:
The AIM2 protein is integral to the immune system, recognizing cytosolic double-stranded DNA and triggering inflammasome assembly. This action leads to the activation of caspase-1, promoting the secretion of inflammatory cytokines and pyroptosis. AIM2's ability to sense DNA damage and mediate cell death underscores its importance in maintaining cellular integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of AIM2 offers promising avenues for drug discovery. Its dual role in immune response activation and tumor suppression, through the inhibition of cell proliferation pathways, positions AIM2 as a compelling target for developing treatments for autoimmune diseases and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.